Physician profile
Soling Li
NPI 1649233925
$11,107.12
in general payments reported to CMS, 2019-2025
37 companies · $1,202 in 2025
The $1,202 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,834 · 2020: $1,108 · 2021: $1,393 · 2022: $1,700 · 2023: $2,049 · 2024: $1,821 · 2025: $1,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,061 · Education: $10.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,061.17 |
| Education | $10.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,175.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,861.73 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $1,620.16 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Gilead Sciences, INC. | $1,411.15 | 2019-2025 | |
| Lilly USA, LLC | $794.58 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $375.83 | 2019-2025 | |
| Almatica Pharma LLC | $294.72 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Bayer Healthcare Pharmaceuticals INC. | $290.28 | 2023-2025 | |
| Idorsia Pharmaceuticals US INC | $254.49 | 2022-2024 | Quviviq |
| Pfizer INC. | $232.26 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $204.07 | 2022-2023 | Xarelto |
| Paratek Pharmaceuticals, INC. | $182.17 | 2021-2024 | Nuzyra |
| Kvk-Tech, INC. | $181.55 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $180.75 | 2019-2022 | |
| Amgen INC. | $126.18 | 2023-2025 | Krystexxa, Otezla, Repatha |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.28 | 2019-2024 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $110.24 | 2021 | |
| Abbott Laboratories | $96.12 | 2024-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $84.47 | 2019-2025 | Veozah |
| Eisai INC. | $72.32 | 2020-2021 | |
| Amarin Pharma, INC. | $65.43 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $51.47 | 2023 | Lyvispah |
| Phathom Pharmaceuticals, INC. | $46.43 | 2024 | Voquezna |
| Redhill Biopharma INC. | $38.40 | 2020 | |
| Novartis Pharmaceuticals Corporation | $34.18 | 2022-2023 | |
| Corcept Therapeutics | $23.69 | 2021 | |
| Seqirus USA INC | $20.97 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $20.16 | 2024 | Zoryve |
| Sanofi Pasteur INC. | $19.32 | 2025 | |
| Supernus Pharmaceuticals, INC. | $18.24 | 2022 | |
| Dermira, INC. | $16.15 | 2020 | |
| Lucid Diagnostics INC. | $14.89 | 2022 | |
| Ironshore Pharmaceuticals INC. | $14.52 | 2019 | |
| Allergan, INC. | $13.64 | 2020 | |
| Horizon Therapeutics Plc | $13.62 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.20 | 2024 | Xifaxan |
| Nalpropion Pharmaceuticals LLC | $13.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Soling Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.